Abstract:Alzheimer's disease (AD) is a neurodegenerative disease and the most frequent cause of dementia. It is characterized by the accumulation in the brain of two pathological protein aggregates: amyloid-β peptides (Aβ) and abnormally phosphorylated tau. The progressive cognitive decline observed in patients strongly correlates with the synaptic loss. Many lines of evidence suggest that soluble forms of Aβ accumulate into the brain where they cause synapse degeneration. Stopping their spreading and/or targeting the pathophysiological mechanisms leading to synaptic loss would logically be beneficial for the patients. However, we are still far from understanding these processes. Our objective was therefore to develop a versatile model to assay and study Aβ-induced synaptotoxicity. We integrated a microfluidic device that physically isolates synapses from presynaptic and postsynaptic neurons with a microelectrode array. We seeded mouse primary cortical cells in the presynaptic and postsynaptic chambers. After functional synapses have formed in the synaptic chamber, we exposed them to concentrated conditioned media from cell lines overexpressing the wild-type or mutated amyloid precursor protein and thus secreting different levels of Aβ. We recorded the neuronal activity before and after exposition to Aβ and quantified Aβ's effects on the connectivity between presynaptic and postsynaptic neurons. We observed that the application of Aβ on the synapses for 48 h strongly decreased the interchamber connectivity without significantly affecting the neuronal activity in the presynaptic or postsynaptic chambers. Thus, through this model, we are able to functionally assay the impact of Aβ peptides (or other molecules) on synaptic connectivity and to use the latter as a proxy to study Aβ-induced synaptotoxicity. Moreover, since the presynaptic, postsynaptic, and synaptic chambers can be individually targeted, our assay provides a powerful tool to evaluate the involvement of candidate genes in synaptic vulnerability and/or test therapeutic strategies for AD.

Advances in microfluidic chips targeting toxic aggregation proteins for neurodegenerative diseases

[In Vitro Pathological Model of Alzheimer's Disease Based on Neuronal Network Chip and Its Real-Time Dynamic Analysis].

Multi-site Dynamic Recording for Aβ Oligomers-Induced Alzheimer's Disease in Vitro Based on Neuronal Network Chip.

Neuropathogenesis-on-chips for neurodegenerative diseases

Microfluidics-Based Systems in Diagnosis of Alzheimer’s Disease and Biomimetic Modeling

Sensor-integrated brain-on-a-chip platforms: Improving the predictive validity in neurodegenerative research

Modeling Neurodegenerative Diseases Using In Vitro Compartmentalized Microfluidic Devices

Microfluidic Brain-on-a-Chip: Perspectives for Mimicking Neural System Disorders

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Microenvironment-tailored Nanoassemblies for the Diagnosis and Therapy of Neurodegenerative Diseases

Integration of Microfluidic Devices with Microelectrode Arrays to Functionally Assay Amyloid-β-Induced Synaptotoxicity

A human induced pluripotent stem cell-derived cortical neuron human-on-a chip system to study Aβ42 and tau-induced pathophysiological effects on long-term potentiation

Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets

Neurons as biosensors for discriminating neurological disorders in a brain-on-chip platform: Application to Alzheimer s Disease using patient CSF

Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption

On-chip modeling of physiological and pathological blood-brain barrier microenvironment for studying glial responses to neuroinflammation

Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications

Development of small molecules for disrupting pathological amyloid aggregation in neurodegenerative diseases

Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Emerging Nanotechnology for Treatment of Alzheimer's and Parkinson's Disease